Search
Now showing items 1-3 of 3
Chronic ethanol use in alcoholic beverages by HIV-infected patients affects the therapeutic window of stavudine, lamivudine and nevirapine during the 9-month follow-up period: using chronic alcohol-use biomarkers
(Journal of Basic and Clinical Physiology and Pharmacology, 2013)
Background: Chronic ethanol use is a global problem
including among HIV-infected patients on stavudine/
lamivudine/nevirapine (d4T/3TC/NVP) regimen. The
study determined the effect of chronic ethanol use on the
therapeutic ...
Chronic alcohol use affects therapeutic steady state plasma drug concentrations of stavudine, lamivudine and nevirapine in HIV-infected patients during 9 months follow up period: WHO AUDIT tool application
(International Journal of Basic & Clinical Pharmacology, 2013)
Chronic alcohol consumption is a common problem among the HIV-infected patients on HAART. The study determined the effect of chronic alcohol use on steady state plasma drug concentrations of stavudine (d4T), lamivudine ...
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study
(BMC Infectious Diseases, 2013)
Background: HIV infection, anti-tuberculosis and efavirenz therapy are associated with neuropsychological effects.
We evaluated the influence of rifampicin cotreatment, efavirenz pharmacokinetics and pharmacogenetics ...